Corporate Venturer

Gotham goes to $54m in series A
Cornell spinout Gotham Therapeutics has come out of stealth with a series A round co-led by SR One, Versant Ventures and Forbion.
Vančura leaves RBVC to join Imec
Ellis seeks new ventures at OSU
Zachary Ellis has joined Ohio State University as director of new ventures, leaving behind his position at Pepsi where he was responsible for driving corporate venturing activities.
Zipkin flies to Parker Institute
Takeda Ventures senior investment director Ilan Zipkin has become the second high-profile departure from the unit in four months to join the Parker Institute for Cancer Immunotherapy.
Flynn resurfaces at Tyton Partners
Rich Flynn, who stepped down from his position as president of Apollo Education Ventures in April, has joined Tyton Partners as managing director.
GSK launches $5m fund
Bristol-Myers Squibb and Pfizer have a heart
Non-profit organisations including Regents of Michigan University are to receive more than a combined $1m in charitable donations.
Takeda shakes up external innovation
Juan Harrison has moved from Takeda Ventures (TVI) to head up New Frontier Science (NFS), a new unit that aims to build relationships with academics and entrepreneurs developing disruptive ideas to improve patients' lives.

Other News

J&J sets up four centres
By creating centres of excellence around the world, J&J is expected to gain the flexibility and resources to invest from early to later stages and work with different types of entrepreneurs - whether from academia, venture capital-backed companies or incubating ideas internally.
Gonnissen reemerges at QBIC
The inter-university venturing QBIC Fund is the successor of the Baekeland II-Fund of UGent and the BI3-fund of VUB.

Editor's Picks

No posts to show.

test reg


Not yet subscribed?

See your subscription offers here